American Regent v. Dr. Reddy’s Laboratories: IV Selenium Patent Consolidated Action
American Regent, Inc. asserted US Patent No. 11,998,565 covering intravenous selenious acid formulations against Dr. Reddy’s Laboratories in New Jersey federal court. Filed in July 2024 and closed within 128 days, this case was one of 13 parallel ANDA infringement actions consolidated into a single proceeding — signalling a broad enforcement campaign across the generic pharmaceutical industry.
A 13-front ANDA campaign over intravenous selenium IP
On July 16, 2024, American Regent, Inc. filed simultaneous infringement actions against 13 separate generic pharmaceutical defendants in the District of New Jersey, each asserting US Patent No. 11,998,565 covering selenious acid intravenous solution formulations used to deliver selenium supplementation. The action against Dr. Reddy’s Laboratories, Ltd. — Case No. 2:24-cv-07799 — is one node in a coordinated enforcement wave consistent with Hatch-Waxman ANDA litigation strategy.
The case closed on November 21, 2024, just 128 days after filing, when all parties stipulated to consolidation of all 13 related actions into the lead docket, Civil Action No. 2:24-cv-7791. This procedural consolidation does not represent a merits ruling; the underlying infringement claims against Dr. Reddy’s remain live and are now adjudicated within the consolidated proceeding. No dismissal, settlement, or substantive judgment was entered in this individual docket.
The rapid consolidation — achieved before any claim construction or substantive motion practice — suggests coordinated case management by all parties and the court to avoid duplicative proceedings across 13 defendants. The public record for this individual docket is silent on licensing discussions, claim-specific disputes, or any defendant-specific defences Dr. Reddy’s may raise within the consolidated action, which remains ongoing.
Filing to Case Consolidated in 128 days
128-day duration from filing to consolidation order — faster than typical ANDA first-instance resolution
Case consolidated: what the order means for both parties
Consolidation closes the docket — litigation continues
Case consolidation under Federal Rule of Civil Procedure 42(a) allows a court to combine actions sharing common questions of law or fact. Here, all 13 ANDA cases were merged into lead docket 2:24-cv-7791. The individual docket 2:24-cv-07799 is administratively closed, but Dr. Reddy’s remains a named defendant with active obligations in the consolidated action. No merits ruling has been issued.
FRCP 42(a) consolidationARI preserves claims against all 13 defendants simultaneously
Consolidation is generally advantageous to the patent holder in multi-defendant ANDA scenarios: American Regent can pursue a single claim construction record and trial schedule against all generic challengers at once, reducing cost and inconsistency risk. The patent — US11998565B2 — remains fully asserted and the 30-month stay mechanism under Hatch-Waxman may still be operative, preventing FDA approval of generic selenium IV products during litigation.
Patent rights preservedDr. Reddy’s faces consolidated proceedings with 12 co-defendants
Dr. Reddy’s now litigates alongside 12 other generic manufacturers including Cipla, Sun Pharma, Hikma, and Zydus. Consolidation can diffuse individual litigation costs but also limits each defendant’s ability to pursue bespoke case management strategies. Dr. Reddy’s invalidity and non-infringement arguments will be developed within a shared briefing and discovery framework, which may constrain litigation flexibility.
Consolidated defence postureIV selenium market entry delayed across the generic landscape
With 13 generic manufacturers simultaneously blocked from independent docket proceedings and potentially subject to Hatch-Waxman’s 30-month stay, the branded selenious acid IV market — serving patients requiring intravenous selenium supplementation — is shielded from generic entry during litigation. The outcome of the consolidated action will set the enforceability benchmark for US11998565B2 across the entire generic selenium IV sector.
Broad market entry delay riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Specialty pharmaceutical company — holder of US11998565B2 for IV selenious acid formulationsSearch in Eureka ↗ |
| Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Indian multinational generic pharmaceutical manufacturer and its US subsidiarySearch in Eureka ↗ |
| Co-Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | Gene Y. Kang | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Gregory D. Miller | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | MARCUS O. TUBIN | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Timothy P. Gonzalez | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Rivkin Radler LLP | Law Firm | Representing Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects a stipulation by all parties — not a judicial finding on the merits. The verdict text documents the breadth of ARI’s enforcement campaign: 13 defendants, a single shared patent, and a coordinated request to consolidate. The phrase ‘good cause exists to consolidate’ is a procedural threshold, not a substantive ruling. For Dr. Reddy’s, the practical effect is that its ANDA defence now proceeds within a multi-defendant framework, where discovery, claim construction, and trial scheduling will be governed by the lead docket judge rather than independently managed.
US11998565B2 — Intravenous Selenious Acid Formulations
US Patent No. 11,998,565 (application number US18/124,391) protects intravenous selenious acid formulations delivering selenium at specified concentrations — including 60 mcg selenium/mL and 6 mcg selenium/mL presentations. The patent covers a critical parenteral nutrition component used in clinical settings where patients cannot absorb selenium enterally. The application number suggests a relatively recent prosecution pathway, consistent with ARI’s strategy to extend IP protection over established but reformulated essential trace element products.
For the generic pharmaceutical sector, US11998565B2 represents a significant barrier to market entry for IV selenium products — a niche but clinically essential category used in ICU, oncology, and long-term parenteral nutrition patients. The breadth of the enforcement campaign (13 defendants) suggests ARI views this patent as a strong exclusivity instrument. Any company holding an ANDA for intravenous selenious acid solution must now navigate this patent’s claims before receiving FDA approval, making it one of the most commercially consequential IV micronutrient patents currently in active litigation.
Should you run an FTO analysis against US11998565B2?
If your organisation is developing, manufacturing, or commercialising intravenous selenious acid products — or any parenteral selenium formulation — US11998565B2 is now an unavoidable clearance priority. American Regent’s decision to assert this patent simultaneously against 13 ANDA filers signals aggressive enforcement intent. Product teams working on IV micronutrient formulations, parenteral nutrition components, or trace element injectables should treat this patent as a live infringement risk requiring formal FTO assessment before any ANDA submission or commercial launch.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US11998565B2 against your specific formulation parameters — concentration ranges, excipient profiles, and dosage form characteristics — to identify freedom-to-operate gaps or design-around opportunities. Eureka also surfaces the full prosecution history, enabling your IP team to assess file wrapper estoppel and claim differentiation relative to the 13 defendants already named in the consolidated New Jersey action.
Run a freedom-to-operate analysis on US11998565B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Cases: IV Pharmaceutical Formulation Disputes
Cases involving Hatch-Waxman ANDA infringement actions over intravenous pharmaceutical formulations in the District of New Jersey, the leading venue for such disputes.
What this case signals for the IV pharmaceutical IP landscape
ARI’s coordinated 13-defendant filing is a textbook Hatch-Waxman enforcement play — and the consolidation outcome has strategic implications for all generic IV drug developers.
Simultaneous multi-defendant ANDA filing is a deliberate enforcement strategy
Filing 13 parallel ANDA actions on the same day — each asserting the same patent — is a calculated tactic to trigger the Hatch-Waxman 30-month stay across multiple ANDA filers at once. Generic manufacturers planning IV selenium product launches should treat the consolidated docket as the critical path to market entry clearance.
Consolidation shifts leverage toward the innovator in multi-defendant cases
When defendants are consolidated, each must coordinate defences in a shared forum, often limiting their ability to distinguish their specific ANDA product characteristics. American Regent benefits from a single claim construction ruling that applies uniformly — a structural advantage worth monitoring as the consolidated action progresses in New Jersey.
American v Dr. — key questions answered
This is a Hatch-Waxman ANDA patent infringement action filed by American Regent, Inc. against Dr. Reddy’s Laboratories in the District of New Jersey on July 16, 2024. ARI asserted US Patent No. 11,998,565, which covers intravenous selenious acid formulations. The case was administratively closed on November 21, 2024 after consolidation into lead docket 2:24-cv-7791 alongside 12 parallel actions against other generic manufacturers.
The case was consolidated because ARI filed 13 identical patent infringement actions on the same day against different generic ANDA filers, all asserting US11998565B2. Consolidation under FRCP 42(a) avoids duplicative proceedings. Dr. Reddy’s individual docket is closed, but the company remains an active defendant in the consolidated action under lead case 2:24-cv-7791. No merits ruling has been issued.
US11998565B2 covers intravenous selenious acid solutions used to deliver selenium supplementation parenterally. The products at issue in the Dr. Reddy’s action include selenious acid IV formulations at concentrations of 60 mcg selenium/mL (600 mcg/10 mL vial) and 6 mcg selenium/mL (12 mcg/2 mL vial) — presentations commonly used in parenteral nutrition and critical care settings.
In addition to Dr. Reddy’s Laboratories, American Regent named 12 other defendants: Accord Healthcare, Aspiro Pharma, Cipla USA and Cipla Limited, Eugia Pharma Specialities and Eugia US, Gland Pharma, Hikma Pharmaceuticals USA, Long Grove Pharmaceuticals, RK Pharma, Somerset Therapeutics/Somerset Pharma/Odin Pharmaceuticals, Sun Pharmaceutical Industries, Xiromed LLC and Xiromed Pharma España, and Zydus Pharmaceuticals USA.
Consolidation is a case management procedure and does not itself alter the operation of the Hatch-Waxman 30-month stay. If ARI’s suit was filed within 45 days of receiving notice of Dr. Reddy’s Paragraph IV certification, the 30-month stay would have been triggered independently for that ANDA. The consolidated docket timeline will govern when the stay expires or is superseded by a court judgment on validity and infringement. Legal counsel should verify the specific ANDA filing and notice dates to confirm stay status.
PatSnap Eureka searches patents and litigation data to answer instantly.